TY - JOUR
T1 - Solid-in-oil nanodispersions for intranasal vaccination
T2 - Enhancement of mucosal and systemic immune responses
AU - Kong, Qingliang
AU - Kitaoka, Momoko
AU - Tahara, Yoshiro
AU - Wakabayashi, Rie
AU - Kamiya, Noriho
AU - Goto, Masahiro
N1 - Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (S) 16H06369 from the Ministry of Education, Culture, Sports, Science, and Technology of Japan , and also by Research Fellowships of the JSPS for Young Scientists (Q. Kong).
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/12/15
Y1 - 2019/12/15
N2 - En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.
AB - En masse vaccination is a promising strategy for combatting infectious diseases. Intranasal vaccination is a viable route of mass vaccination, and it could be performed easily via needle-free administration. However, it is not widely used because it tends not to evoke sufficient immunity. The aim of the present study was to improve the performance of intranasal vaccination by extending the amount of time that administered antigens remain in the nasal cavity, and enhancing immune responses via a nanocarrier-based adjuvant. A simple and safe solid-in-oil (S/O) system was investigated as a nanocarrier in intranasal vaccination. S/O nanodispersions are oil-based dispersions of antigens coated with surfactants. Because of the mucoadhesive capacities of surfactant and oil they have high potential to extend the amount of time that administered antigens remain in the nasal cavity, and can induce strong immune responses due to a nanocarrier-based adjuvant effect. In nasal absorption experiments antigens administered intranasally via S/O nanodispersions remained in the nasal cavity longer and induced strong mucosal and systemic immune responses. Histopathology analysis indicated that S/O nanodispersions did not modify the nasal epithelium or cilia, suggesting non-toxicity of the carrier. These results indicate the potential of intranasal vaccination using S/O nanodispersions for future vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85074332604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074332604&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2019.118777
DO - 10.1016/j.ijpharm.2019.118777
M3 - Article
C2 - 31678377
AN - SCOPUS:85074332604
SN - 0378-5173
VL - 572
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 118777
ER -
